Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Overview of attention for article published in New England Journal of Medicine, December 2022
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (99th percentile)
-
High Attention Score compared to outputs of the same age and source (82nd percentile)
Mentioned by
- news
- 63 news outlets
- blogs
- 2 blogs
- policy
- 3 policy sources
- 112 X users
- 1 Facebook page
- wikipedia
- 1 Wikipedia page
- 1 Redditor
- guideline
- 5 clinical guideline sources
- podcasts
- 2 podcasts
Readers on
- mendeley
- 291 Mendeley